|
|
|
| Disease burden of malignant tumor in Guiyang City |
| XU Luting1, TIAN Yuhan1, PU Yan1,2
|
1. School of Public Health, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550000, China;
2. Guiyang Center for Disease Control and Prevention (Guiyang Institute of Public Health Supervision), Guiyang, Guizhou 550018, China |
|
|
|
|
Abstract Objective To understand the disease burden of malignant tumor in Guiyang City, Guizhou Province in 2022, so as to provide references for strengthening the prevention and control of malignant tumors. Methods Data on the incidence and mortality of malignant tumor in Guiyang City in 2022 were collected through the tumor follow-up registration and death surveillance system of the "Healthy Guizhou Smart Disease Control Cloud Platform". The Chinese population-standardized incidence and world population-standardized incidence were calculated using the standard age structure from the Seventh National Population Census in 2020 and Segi's world standard population structure, respectively. A descriptive analysis was conducted to examine the characteristics of the disease burden of malignant tumor by gender, region and age group. Results In 2022, the crude incidence, Chinese population-standardized incidence and world population-standardized incidence of malignant tumor in Guiyang City were 236.14/105, 182.09/105 and 175.20/105, respectively. The crude mortality, Chinese population-standardized mortality and world population-standardized mortality were 136.97/105, 97.81/105 and 97.69/105, respectively, and the DALY rate was 1 445.62/105. The crude incidence (P<0.05), Chinese population-standardized incidence, and world population-standardized incidence of malignant tumor were higher in females than in males, while the crude mortality rate (P<0.05), the Chinese population-standardized mortality, world population-standardized mortality rate, and DALY rate were all lower in females than in males. The Chinese population-standardized incidence and world population-standardized incidence of malignant tumor in urban areas were higher than in rural areas, while the crude mortality (P<0.05), Chinese population-standardized mortality, world population-standardized mortality, and DALY rate were all lower in urban areas than in rural areas. The crude incidence of malignant tumor was lower in the 0-<40 age group, increased rapidly after the age of 40 years, and peaked in the ≥85 age group; the crude mortality and DALY rate were lower in the 0-<45 age group, increased rapidly after the age of 45 years, and peaked in the ≥85 and 80-<85 age groups, respectively. Lung cancer ranked first in crude incidence, crude mortality, and DALY rate of malignant tumor. Thyroid cancer and colorectal cancer, colorectal cancer and liver cancer, and liver cancer and colorectal cancer ranked second and third in crude incidence, crude mortality, and DALY rate, respectively. Conclusion In 2022, the disease burden of malignant tumor in Guiyang City was characterised by higher incidence in females and urban residents, higher mortality in males and rural residents, higher risks of incidence and mortality in middle-aged and elderly populations, with lung cancer, colorectal cancer, and liver cancer being the key diseases for prevention and control.
|
|
Received: 07 January 2026
Revised: 02 April 2026
Published: 27 May 2026
|
|
|
|
|
|
[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] YANG G H,WANG Y,ZENG Y X,et al.Rapid health transition in China,1990-2010:findings from the Global Burden of Disease Study 2010[J].Lancet,2013,381(9882):1987-2015.
[3] BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
[4] HAN B F,ZHENG R S,ZENG H M,et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Cent,2024,4(1):47-53.
[5] 肖瑶,张莹,凌鑫,等.2015—2021年我国城乡居民主要死因分析[J].中国预防医学杂志,2024,25(12):1520-1525.
[6] 吉维,周婕,刘涛,等.2019年贵州省肿瘤登记地区恶性肿瘤发病与死亡特征及2015—2019年趋势分析[J].中国肿瘤,2025,34(3):178-187.
[7] 杜灵彬,邱雨,李辉章,等.2021年浙江省肿瘤登记地区恶性肿瘤发病和死亡特征分析[J].预防医学,2025,37(10):973-978.
[8] 蔡玥,伍晓玲,薛明,等.恶性肿瘤疾病负担研究方法与进展[J].中国卫生信息管理杂志,2015,12(2):136-142.
[9] 国家癌症中心.中国肿瘤登记工作指导手册(2016)[M].北京:人民卫生出版社,2016.
[10] 陈茹,魏文强.《2022年中国癌症发病和死亡报告》解读[J].中国实用外科杂志,2025,45(2):174-180.
[11] 任露露,闵艺璇,顾嘉昌,等.2021年江苏省宜兴市恶性肿瘤流行现状及2016—2021年变化趋势分析[J].现代肿瘤医学,2026,34(1):105-111.
[12] 刘洋,王颖,马祥,等.2021年辽宁省营口市城市居民恶性肿瘤发病与死亡分析[J].实用肿瘤学杂志,2025,39(05):400-404.
[13] 周子寒,李秋林,余家华,等.2018年广西恶性肿瘤流行情况及疾病负担分析[J].中国癌症防治杂志,2023,15(2):181-189.
[14] 王裕新,潘凯枫,李文庆.2022全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2024,10(3):1-16.
[15] 阿迪拉·苏力旦,夏依达·乌斯满江,沙吾拉西·热加甫,等.2020年新疆肿瘤登记地区甲状腺癌流行特征及2016—2020年变化趋势分析[J].预防医学,2025,37(10):1020-1023,1028.
[16] 成姝雯,董婷,张新,等.2021年四川省肿瘤登记地区恶性肿瘤发病和死亡特征分析[J].预防医学,2025,37(10):1002-1008.
[17] 吴琪,范伯男,李岩.2022全球癌症统计报告分析解读:中国与世界癌症疾病负担与流行趋势[J].诊断学理论与实践,2025,24(2):135-145.
[18] 张芷悦,何慧婧,单广良,等.甲状腺癌的流行病学现状及其影响因素研究进展[J].中国癌症杂志,2025,35(1):21-29.
[19] 项彩英,陈颖,汪德兵,等.2021年浙江省肿瘤登记地区甲状腺癌发病与死亡特征及2000—2021年变化趋势分析[J].中国肿瘤,2025,34(10):756-763.
[20] 陈裕玺,汤一帆,王筠惠,等.2010—2020年烟台市芝罘区恶性肿瘤疾病负担及流行趋势研究[J].中国卫生统计,2025,42(3):382-386.
[21] XIA C F,DONG X S,LI H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants[J].Chin Med J,2022,135(5):584-590.
[22] 王志如,贾小芳,刘梦冉,等.2018年我国15省45~64岁中年人共病现状及其影响因素——基于关联规则分析[J].环境与职业医学,2024,41(7):768-773.
[23] 马晓波,马小桐,马建清,等.1990—2021年中国肿瘤疾病负担分析[J].医学新知,2025,35(8):885-891. |
|
|
|
